氯喹对泰国间日疟的治疗效果评估。

Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.

作者信息

Vijaykadga S, Rojanawatsirivej C, Congpoung K, Wilairatana P, Satimai W, Uaekowitchai C, Pumborplub B, Sittimongkol S, Pinyorattanachote A, Prigchoo P

机构信息

Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.

出版信息

Southeast Asian J Trop Med Public Health. 2004 Sep;35(3):566-9.

PMID:15689067

Abstract

Chloroquine-resistant Plasmodium vivax has been reported in some Asian countries. In 2003, 161 patients infected with vivax malaria were treated according to the Thai National Drug Policy, with oral chloroquine (approximately 25 mg base/kg body weight, administered over 3 days) followed by primaquine on day 28 (15 mg daily for 14 days). All the patients were initially cured after chloroquine treatment, clearing their parasitemias within 7 days. Only one patient presented with parasitemia at 28 days. These data indicate that chloroquine is still effective for the treatment of patients with vivax malaria in Thailand.

摘要

在一些亚洲国家已报告出现对氯喹耐药的间日疟原虫。2003年，161例间日疟患者根据泰国国家药物政策接受治疗，口服氯喹（约25毫克碱基/千克体重，分3天服用），并在第28天加服伯氨喹（每天15毫克，共14天）。所有患者在氯喹治疗后最初均获治愈，7天内疟原虫血症消失。仅1例患者在第28天出现疟原虫血症。这些数据表明，氯喹在泰国对间日疟患者的治疗仍然有效。